StockMacro
Menu

Propanc Biopharma

$1.78 -90% in 6 monthsMarket cap $1.7M

PPCB on XNAS, Health Care, Propanc Biopharma, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 99% in a year as a delisting notice was filed, leaving $258K in cash.

  • BadNet loss of $22.6M over the last 12 months
  • WatchPast S-1 filers trailed their sector by 23.8 points over 6 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Industry
Pharmaceutical preparations (Health Care)
Employees
2
Website
propanc.com
Listed
Nasdaq, US
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $8.6M.
Quarter to 31 Dec 2021: revenue –, net income -$800KQuarter to 31 Mar 2022: revenue –, net income -$463KQuarter to 30 Sep 2022: revenue –, net income -$617KQuarter to 31 Dec 2022: revenue –, net income -$485KQuarter to 31 Mar 2023: revenue –, net income -$810KQuarter to 30 Jun 2023: revenue –, net income -$748KQuarter to 30 Sep 2023: revenue –, net income -$351KQuarter to 31 Dec 2023: revenue –, net income -$584KQuarter to 31 Mar 2024: revenue –, net income -$527KQuarter to 30 Jun 2024: revenue –, net income -$359KQuarter to 30 Sep 2024: revenue –, net income -$354KQuarter to 31 Dec 2024: revenue –, net income -$430KQuarter to 31 Mar 2025: revenue –, net income -$54.1MQuarter to 30 Jun 2025: revenue –, net income -$4.1MQuarter to 30 Sep 2025: revenue –, net income -$4.8MQuarter to 31 Dec 2025: revenue –, net income -$3.1MQuarter to 31 Mar 2026: revenue –, net income -$6.4MQuarter to 30 Jun 2026: revenue –, net income -$4.6MQuarter to 30 Sep 2026: revenue –, net income -$8.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $54.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$8.6M
30 Jun 2026–-$4.6M
31 Mar 2026–-$6.4M
31 Dec 2025–-$3.1M
30 Sep 2025–-$4.8M
30 Jun 2025–-$4.1M
31 Mar 2025–-$54.1M
31 Dec 2024–-$430K
30 Sep 2024–-$354K
30 Jun 2024–-$359K
31 Mar 2024–-$527K
31 Dec 2023–-$584K
30 Sep 2023–-$351K
30 Jun 2023–-$748K
31 Mar 2023–-$810K
31 Dec 2022–-$485K
30 Sep 2022–-$617K
31 Mar 2022–-$463K
31 Dec 2021–-$800K
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$22.6M -$63.4M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -211% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $258K $603K
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $6.74
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.26 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Propanc BiopharmaPPCB (this company) $1.7Mloss–––
Kala BIOKALA $1.7Mloss–––
Sunshine BiopharmaSBFM $1.8Mloss0.05-5.2%-17.5%
Jupiter NeurosciencesJUNS $1.6Mloss–––
GenprexGNPX $1.9Mloss–––
Decoy TherapeuticsDCOY $2.0Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

–

No data for this company

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

7.4%

77K shares held by 13F filers (30 Sep 2026) of 1.0M outstanding (12 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.9%

20K shares sold short (30 Oct 2026) of 1.0M outstanding (12 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.0

20K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-61%

50K shares sold short in the report before, 20K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

67%

67% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

1

1 article in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

1 article in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $1.78 on 20 Nov 2026, -99% over 12 months (12-month range $1.64 to $235.62)

  • Sharp change
  • 8-K and other filings
Capital spending per quarter. Capital spending $154 in the latest quarter.
Institutional holders (13F filers). 5 13F filers reported holding it in the latest 13F quarter, +67% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: insider net buying (open market), h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
29 Oct 20268-K and other filingsDelisting notice or listing transfer
5 Oct 20268-K and other filingsRegistered new securities for sale (S-1)
17 Jul 20268-K and other filingsRegistered new securities for sale (S-1)
14 Jul 20268-K and other filingsDirector or officer change
14 Jul 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Jun 2026Sharp changeShort interest spike: short interest spike, 617K vs usual 191K (2026-05-15); 22036.1x the same period a year earlier
10 Apr 20268-K and other filingsRegistered new securities for sale (S-1)
26 Feb 20268-K and other filingsDirector or officer change
26 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Feb 20268-K and other filingsRegistered new securities for sale (S-1)
2 Feb 20268-K and other filingsRegistered new securities for sale (S-1)
7 Jan 20268-K and other filingsDelisting notice or listing transfer
30 Dec 20258-K and other filingsRegistered new securities for sale (S-1)
19 Aug 20258-K and other filingsDirector or officer change
13 Aug 20258-K and other filingsDirector or officer change
13 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Jul 20258-K and other filingsRegistered new securities for sale (S-1)
30 May 20258-K and other filingsRegistered new securities for sale (S-1)
25 Apr 20258-K and other filingsRegistered new securities for sale (S-1)
8 Apr 20258-K and other filingsRegistered new securities for sale (S-1)
2 Apr 20258-K and other filingsRegistered new securities for sale (S-1)
31 Mar 20258-K and other filingsRegistered new securities for sale (S-1)
30 Oct 20248-K and other filingsRegistered new securities for sale (S-1)
15 Oct 2024Sharp changeShort interest spike: short interest spike, 1.6M vs usual 35K (2024-09-30); 53.4x the same period a year earlier
1 Oct 2024Sharp changeShort interest spike: short interest spike, 1.9M vs usual 33K (2024-09-13); 177.0x the same period a year earlier
17 Sep 2024Sharp changeShort interest spike: short interest spike, 1.6M vs usual 33K (2024-08-30); 51.7x the same period a year earlier
27 Aug 2024Sharp changeShort interest spike: short interest spike, 2.9M vs usual 31K (2024-08-15); 96.6x the same period a year earlier
14 Feb 20248-K and other filingsReport will be filed late
3 Nov 20238-K and other filingsPrivate placement of securities (Form D)
26 Oct 20238-K and other filingsPrivate placement of securities (Form D)
10 Oct 20238-K and other filingsRegistered new securities for sale (S-1)
6 Oct 20238-K and other filingsRegistered new securities for sale (S-1)
31 Aug 20238-K and other filingsPrivate placement of securities (Form D)
31 Aug 20238-K and other filingsPrivate placement of securities (Form D)
30 Aug 20238-K and other filingsPrivate placement of securities (Form D)
16 Aug 20238-K and other filingsPrivate placement of securities (Form D)
15 Aug 20238-K and other filingsPrivate placement of securities (Form D)
11 Aug 20238-K and other filingsRegistered new securities for sale (S-1)
8 Aug 20238-K and other filingsA major agreement ended
13 Dec 2022Sharp changeShort interest spike: short interest spike, 565K vs usual 32K (2022-11-30); 148.1x the same period a year earlier
1 Nov 20228-K and other filingsDirector or officer change
1 Nov 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Feb 20228-K and other filingsRegistered new securities for sale (S-1)
3 Feb 20228-K and other filingsRegistered new securities for sale (S-1)
Capital spending per quarter
Quarter ended 30 Sep 2025: $2K; public on 15 Nov 2025
Quarter ended 31 Dec 2025: $2K; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $154; public on 15 May 2026
Institutional holders (13F filers)
30 Sep 2025 report: 3; public on 14 Nov 2025
31 Dec 2025 report: 5; public on 17 Feb 2026
31 Mar 2026 report: 6; public on 15 May 2026
30 Jun 2026 report: 5; public on 14 Aug 2026
30 Sep 2026 report: 5; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $458K (30 Sep 2026), 8.0× its normal quarter; higher than 93% of its own history.
  • Short interest spike: had 617K shares sold short in the 15 May 2026 report, 22,036× the same report last year Public on 28 May 2026.
  • Capital spending per quarter: Capital spending $154 in the latest quarter.
  • Institutional holders (13F filers): 5 13F filers reported holding it in the latest 13F quarter, +67% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

In 12 months: 6 share registrations, 2 delisting notices, 2 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
29 Oct 2026Delisting notice or listing transfer8-K
5 Oct 2026Registered new securities for sale (S-1)S-1
17 Jul 2026Registered new securities for sale (S-1)S-1
14 Jul 2026Director or officer change8-K
10 Apr 2026Registered new securities for sale (S-1)S-1
26 Feb 2026Director or officer change8-K
19 Feb 2026Registered new securities for sale (S-1)S-1/A
2 Feb 2026Registered new securities for sale (S-1)S-1

The 5 newest of 37 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 29 Oct 2026Filings record

    Delisting notice or listing transfer

  2. 5 Oct 2026Filings record

    Registered new securities for sale (S-1)

  3. 17 Jul 2026Filings record

    Registered new securities for sale (S-1)

  4. 14 Jul 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 14 Jul 2026Filings record

    Director or officer change

  6. 28 May 2026Short interest and volume change

    had 617K shares sold short in the 15 May 2026 report, 22,036× the same report last year.

    Same report last year: 28; its normal report is 191K.

    See the evidence
    This period
    617K (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    191K
    Typical spread (median absolute deviation)
    62K
    How far from its usual level
    +4.7
    Same report last year
    28
    History used
    3,059 days
    2025-03-31: 2042025-04-15: 2132025-05-15: 282025-06-13: 4382025-06-30: 2552025-07-31: 2,1392025-08-15: 8122025-08-29: 172K2025-09-15: 188K2025-09-30: 212K2025-10-15: 185K2025-10-31: 194K2025-11-14: 257K2025-11-28: 168K2025-12-15: 237K2025-12-31: 231K2026-01-15: 195K2026-01-30: 399K2026-02-13: 338K2026-02-27: 249K2026-03-13: 585K2026-03-31: 144K2026-04-15: 202K2026-04-30: 524K2026-05-15: 617K
    the 15 May 2026 report24 earlier reportsnormal: 191K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 10 Apr 2026Filings record

    Registered new securities for sale (S-1)

  8. 26 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 26 Feb 2026Filings record

    Director or officer change

  10. 19 Feb 2026Filings record

    Registered new securities for sale (S-1)

  11. 2 Feb 2026Filings record

    Registered new securities for sale (S-1)

  12. 7 Jan 2026Filings record

    Delisting notice or listing transfer

  13. 30 Dec 2025Filings record

    Registered new securities for sale (S-1) (dated 29 Dec 2025)

  14. 19 Aug 2025Filings record

    Director or officer change

  15. 13 Aug 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 13 Aug 2025Filings record

    Director or officer change

  17. 28 Jul 2025Filings record

    Registered new securities for sale (S-1)

  18. 30 May 2025Filings record

    Registered new securities for sale (S-1)

  19. 25 Apr 2025Filings record

    Registered new securities for sale (S-1)

  20. 8 Apr 2025Filings record

    Registered new securities for sale (S-1)

  21. 2 Apr 2025Filings record

    Registered new securities for sale (S-1)

  22. 31 Mar 2025Filings record

    Registered new securities for sale (S-1)

  23. 30 Oct 2024Filings record

    Registered new securities for sale (S-1)

  24. 10 Oct 2024Short interest and volume change

    had 1.6M shares sold short in the 30 Sep 2024 report, 53× the same report last year.

    Same report last year: 30K; its normal report is 35K.

    See the evidence
    This period
    1.6M (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    35K
    Typical spread (median absolute deviation)
    24K
    How far from its usual level
    +30.9
    Same report last year
    30K
    History used
    2,467 days
    2023-07-14: 36K2023-07-31: 34K2023-08-31: 30K2023-09-15: 11K2023-09-29: 30K2023-10-13: 35K2023-10-31: 42K2023-11-15: 11K2023-11-30: 13K2023-12-15: 59K2023-12-29: 742024-01-12: 12K2024-01-31: 20K2024-02-15: 28K2024-02-29: 127K2024-03-28: 6,1942024-04-30: 71K2024-05-15: 78K2024-06-14: 74K2024-06-28: 32K2024-07-31: 154K2024-08-15: 2.9M2024-08-30: 1.6M2024-09-13: 1.9M2024-09-30: 1.6M
    the 30 Sep 2024 report24 earlier reportsnormal: 35K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 25 Sep 2024Short interest and volume change

    had 1.9M shares sold short in the 13 Sep 2024 report, 177× the same report last year.

    Same report last year: 11K; its normal report is 33K.

    See the evidence
    This period
    1.9M (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    33K
    Typical spread (median absolute deviation)
    21K
    How far from its usual level
    +37.0
    Same report last year
    11K
    History used
    2,450 days
    2023-06-30: 29K2023-07-14: 36K2023-07-31: 34K2023-08-31: 30K2023-09-15: 11K2023-09-29: 30K2023-10-13: 35K2023-10-31: 42K2023-11-15: 11K2023-11-30: 13K2023-12-15: 59K2023-12-29: 742024-01-12: 12K2024-01-31: 20K2024-02-15: 28K2024-02-29: 127K2024-03-28: 6,1942024-04-30: 71K2024-05-15: 78K2024-06-14: 74K2024-06-28: 32K2024-07-31: 154K2024-08-15: 2.9M2024-08-30: 1.6M2024-09-13: 1.9M
    the 13 Sep 2024 report24 earlier reportsnormal: 33K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 12 Sep 2024Short interest and volume change

    had 1.6M shares sold short in the 30 Aug 2024 report, 52× the same report last year.

    Same report last year: 30K; its normal report is 33K.

    See the evidence
    This period
    1.6M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    33K
    Typical spread (median absolute deviation)
    21K
    How far from its usual level
    +30.3
    Same report last year
    30K
    History used
    2,436 days
    2023-05-15: 310K2023-06-30: 29K2023-07-14: 36K2023-07-31: 34K2023-08-31: 30K2023-09-15: 11K2023-09-29: 30K2023-10-13: 35K2023-10-31: 42K2023-11-15: 11K2023-11-30: 13K2023-12-15: 59K2023-12-29: 742024-01-12: 12K2024-01-31: 20K2024-02-15: 28K2024-02-29: 127K2024-03-28: 6,1942024-04-30: 71K2024-05-15: 78K2024-06-14: 74K2024-06-28: 32K2024-07-31: 154K2024-08-15: 2.9M2024-08-30: 1.6M
    the 30 Aug 2024 report24 earlier reportsnormal: 33K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 27 Aug 2024Short interest and volume change

    had 2.9M shares sold short in the 15 Aug 2024 report, 97× the same report last year.

    Same report last year: 30K; its normal report is 31K.

    See the evidence
    This period
    2.9M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    31K
    Typical spread (median absolute deviation)
    19K
    How far from its usual level
    +57.3
    Same report last year
    30K
    History used
    2,421 days
    2023-04-28: 1102023-05-15: 310K2023-06-30: 29K2023-07-14: 36K2023-07-31: 34K2023-08-31: 30K2023-09-15: 11K2023-09-29: 30K2023-10-13: 35K2023-10-31: 42K2023-11-15: 11K2023-11-30: 13K2023-12-15: 59K2023-12-29: 742024-01-12: 12K2024-01-31: 20K2024-02-15: 28K2024-02-29: 127K2024-03-28: 6,1942024-04-30: 71K2024-05-15: 78K2024-06-14: 74K2024-06-28: 32K2024-07-31: 154K2024-08-15: 2.9M
    the 15 Aug 2024 report24 earlier reportsnormal: 31K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 14 Feb 2024Filings record

    Report will be filed late

  29. 3 Nov 2023Filings record

    Private placement of securities (Form D)

  30. 26 Oct 2023Filings record

    Private placement of securities (Form D)

  31. 10 Oct 2023Filings record

    Registered new securities for sale (S-1)

  32. 6 Oct 2023Filings record

    Registered new securities for sale (S-1)

  33. 31 Aug 2023Filings record

    Private placement of securities (Form D)

  34. 31 Aug 2023Filings record

    Private placement of securities (Form D)

  35. 30 Aug 2023Filings record

    Private placement of securities (Form D)

  36. 16 Aug 2023Filings record

    Private placement of securities (Form D)

  37. 15 Aug 2023Filings record

    Private placement of securities (Form D)

  38. 11 Aug 2023Filings record

    Registered new securities for sale (S-1)

  39. 8 Aug 2023Filings record

    A major agreement ended

  40. 10 Dec 2022Short interest and volume change

    had 565K shares sold short in the 30 Nov 2022 report, 148× the same report last year.

    Same report last year: 3,817; its normal report is 32K.

    See the evidence
    This period
    565K (the 30 Nov 2022 report)
    Normal report (median of 24 earlier)
    32K
    Typical spread (median absolute deviation)
    29K
    How far from its usual level
    +10.7
    Same report last year
    3,817
    History used
    1,797 days
    2021-09-30: 21K2021-10-15: 1,0822021-10-29: 3,4062021-11-15: 3,8172021-12-15: 20K2022-01-31: 20K2022-02-28: 28K2022-03-15: 27K2022-03-31: 36K2022-04-14: 332K2022-04-29: 17K2022-05-13: 5,0652022-05-31: 61K2022-06-15: 78K2022-06-30: 167K2022-07-15: 230K2022-07-29: 121K2022-08-15: 131K2022-08-31: 29K2022-09-15: 2202022-09-30: 92K2022-10-14: 64K2022-10-31: 100K2022-11-15: 50K2022-11-30: 565K
    the 30 Nov 2022 report24 earlier reportsnormal: 32K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 78 entries; narrow the window or the kind of data to see older ones.

Not listed: 148 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001517681
Ticker
PPCB
Domain
propanc.com
Hq location
C3|CAMBERWELL, VICTORIA|3124 (1 unverified)
Name
Propanc Biopharma, Inc., Propanc Health Group Corp
  • SEC Form 13F institutional holdings86 data points31 Dec 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)213 records16 Feb 2016 to 13 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)756 data points30 Jun 2008 to 12 Nov 2026
  • FINRA short interest (twice monthly)507 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)640 data points15 Aug 2025 to 20 Nov 2026